German Construction Stock News

XTRA:AFX
XTRA:AFXMedical Equipment

A Look At Carl Zeiss Meditec (XTRA:AFX) Valuation After Revenue Guidance Cut And Quarterly Net Loss

Carl Zeiss Meditec (XTRA:AFX) cut its revenue outlook after a weak start to the year, citing softer sales expectations in the US and China as well as pressure from China’s new volume based procurement process. See our latest analysis for Carl Zeiss Meditec. The revenue guidance cut and first quarter net loss arrived after a sharp reset in sentiment, with a 30 day share price return of 32% decline and a 1 year total shareholder return of 50.65% decline, signalling fading momentum despite...
XTRA:FRA
XTRA:FRAInfrastructure

Fraport (XTRA:FRA) Valuation Check As Traffic Recovers And New EV Charging Park Opens

Fraport (XTRA:FRA) is back in focus after two January 2026 updates, rising passenger numbers across its airport portfolio and the opening of a high-speed charging park for electric trucks at Frankfurt Airport. See our latest analysis for Fraport. The recent traffic update and charging park launch come against a backdrop of firm share price momentum, with a 19.70% year to date share price return and a 44.46% one year total shareholder return. This suggests that investors may be reassessing...
XTRA:VOW3
XTRA:VOW3Auto

Volkswagen’s BEV Lead In Europe And Tariff Talks Shape Value Case

Volkswagen, ticker XTRA:VOW3, has overtaken Tesla as Europe's top selling battery electric vehicle brand. The company is also involved in EU China discussions on electric vehicle import tariffs, including matters related to its Cupra brand. These developments affect Volkswagen's position in the European EV market and its approach to cross border sales with China. Volkswagen is a major global automaker with a growing focus on fully electric models, and its brands now play a central role in...
XTRA:SIE
XTRA:SIEIndustrials

Siemens (XTRA:SIE) Valuation Check After 2026 Outlook Upgrade And AI Driven First Quarter Beat

Siemens (XTRA:SIE) is back in focus after raising its fiscal 2026 earnings outlook, supported by a first quarter that exceeded expectations and by strong demand related to artificial intelligence and data center infrastructure. See our latest analysis for Siemens. The latest earnings beat and 2026 guidance upgrade come after a strong run, with the 90 day share price return of 12.58% and a 1 year total shareholder return of 13.84% pointing to momentum that has been building over several years,...
XTRA:DBK
XTRA:DBKCapital Markets

Deutsche Bank Settlement Begins Clearing Monte Dei Paschi Overhang For Investors

Deutsche Bank has reached a confidential settlement with former manager Stefano Foresti in a lawsuit tied to the Monte dei Paschi accounting scandal. The agreement concludes the first of several related cases brought by former employees over their alleged involvement in the affair. The outcome may influence how remaining internal disputes linked to the scandal are handled. For you as an investor looking at XTRA:DBK, this legal development comes with the share price at €29.6. The stock has...
XTRA:VBK
XTRA:VBKOil and Gas

Assessing Verbio (XTRA:VBK) Valuation After Return To Profitability And Higher Biofuel Output

Why Verbio’s latest earnings are in focus Verbio (XTRA:VBK) is back in the spotlight after its second quarter and half year results to 31 December 2025 showed quarterly profitability, higher sales, and increased bioethanol and biomethane production. Those headline figures, together with an earlier share price move ahead of the announcement, have drawn fresh attention from investors who are assessing how the company’s fuel mix and operating scale are affecting the quality of its earnings. See...
XTRA:BVB
XTRA:BVBEntertainment

Borussia Dortmund Q2 EPS Loss Challenges Bullish Profitability Narratives

Borussia Dortmund GmbH Kommanditgesellschaft auf Aktien (XTRA:BVB) has reported Q2 2026 revenue of €143.3 million with a basic EPS loss of €0.04, compared with Q2 2025 revenue of €140.1 million and EPS of €0.06. Over the last few quarters, revenue has moved between €126.7 million and €161.4 million while EPS has ranged from a loss of €0.05 to a profit of €0.21. This latest print keeps the spotlight firmly on how efficiently the club is converting its top line into sustainable earnings. With...
XTRA:FAA
XTRA:FAASoftware

Fabasoft (XTRA:FAA) Margin Compression To 9.7% Challenges Bullish Growth Narrative

Q3 2026 headline numbers set the tone Fabasoft (XTRA:FAA) has put fresh numbers on the table for Q3 2026, reporting revenue of €22.379 million, basic EPS of €0.25 and net income of €2.719 million. Over recent quarters the company has seen revenue move between €21.196 million and €22.852 million, with EPS ranging from €0.091698 to €0.3. This gives investors a clear view of how the top line and EPS have tracked through the last few reporting periods. With a trailing net profit margin of 9.7%...
XTRA:MRK
XTRA:MRKPharmaceuticals

Evaluating Merck KGaA (XTRA:MRK) After Sphingolipids Growth Outlook Fuels Fresh Investor Interest

Future Market Insights projects the global sphingolipids market to reach USD 1,145.6 million by 2035, and Merck KGaA (XTRA:MRK) is identified as a key supplier of high purity sphingolipid products and delivery systems. See our latest analysis for Merck KGaA. Merck KGaA’s role in the sphingolipids market sits against a backdrop of a €127.8 share price, a 10.41% 90 day share price return, and a 5.36% year to date share price return. At the same time, the 1 year total shareholder return of a...
XTRA:NDX1
XTRA:NDX1Electrical

What Nordex (XTRA:NDX1)'s New 220 MW European Orders Mean For Shareholders

In early February 2026, Nordex SE reported new European onshore wind orders totaling 220 MW across the UK, Turkiye, Lithuania and Sweden, all bundled with multi-year service and maintenance agreements that aim to secure long-term turbine performance in both standard and cold-climate sites. These contracts highlight Nordex’s growing strength in cold-climate and community wind projects, where its anti-icing technology and long-duration service deals are becoming central to how it competes for...
XTRA:KCO
XTRA:KCOTrade Distributors

A Look At Klöckner & Co (XTRA:KCO) Valuation After Its Recent Strong Share Price Momentum

Klöckner & Co (XTRA:KCO) has recently attracted investor attention after its share price moved sharply over the past month, with returns also standing out over the past 3 months and past year. See our latest analysis for Klöckner & Co. Klöckner & Co’s recent move to €11.06 comes after a strong run, with a 30-day share price return of 30.89% and a 12-month total shareholder return of 87.88%. This suggests that momentum has been building rather than fading. If this kind of upswing has you...
XTRA:HFG
XTRA:HFGConsumer Retailing

HelloFresh (XTRA:HFG) Valuation Check After Revenue Drop And Missed Q4 2025 Guidance

HelloFresh (XTRA:HFG) is back in focus after its share price dropped sharply, following a reported 9% year on year net revenue decline and missed Q4 2025 guidance that rattled investor confidence. See our latest analysis for HelloFresh. The recent Q4 2025 miss and profit warnings have been reflected in the numbers, with a 7 day share price return of 13.86% and a year to date share price return of 11.88%. Over a longer horizon, the 1 year total shareholder return of 58.47% and 5 year total...
XTRA:LHA
XTRA:LHAAirlines

How A 24-Hour Strike And Mass Disruptions At Lufthansa (XTRA:LHA) Has Changed Its Investment Story

In recent days, Deutsche Lufthansa was hit by a 24-hour strike by pilots and cabin crew over pensions and retirement funding, forcing the cancellation of close to 800 flights and disrupting travel for about 100,000 passengers, although the airline aimed to restore a largely normal schedule by the following day. This industrial action underscores persistent labor cost and pension pressures at Lufthansa, raising questions about how reliably the airline can control its core cost base while...
XTRA:IFX
XTRA:IFXSemiconductor

A Look At Infineon Technologies (XTRA:IFX) Valuation After Q1 Results And Fresh Sales Guidance

Infineon Technologies (XTRA:IFX) is in focus after reporting first quarter 2026 results and pairing them with fresh sales guidance for the second quarter and full fiscal year, giving investors updated benchmarks to assess. See our latest analysis for Infineon Technologies. The results and guidance have landed against a backdrop of solid recent momentum, with a 23.28% 90 day share price return and a 16.93% 1 year total shareholder return suggesting sentiment has strengthened over both shorter...
XTRA:PUM
XTRA:PUMLuxury

Is Puma (XTRA:PUM) Pricing In Its Long-Term Recovery After Multi-Year Share Price Slump?

If you are wondering whether PUMA's current share price really reflects the business, you are not alone. This article is built to help you frame that question clearly. PUMA recently closed at €23.45, with returns of 3.3% over 7 days, 5.0% over 30 days and 4.7% year to date, while the 1 year, 3 year and 5 year returns stand at a 19.4% decline, 59.3% decline and 71.6% decline. Recent coverage around PUMA has focused on how the brand is positioned against global sportswear peers and how...
XTRA:NCH2
XTRA:NCH2Construction

A Look At Thyssenkrupp Nucera (XTRA:NCH2) Valuation After Q1 Loss And Middle East Electrolyzer Win

Earnings and contract wins set the tone for investors thyssenkrupp nucera KGaA (XTRA:NCH2) has drawn attention after first quarter earnings showed lower sales and a small net loss, while management reiterated full year guidance and announced a large electrolyzer contract in the Middle East. See our latest analysis for thyssenkrupp nucera KGaA. At a share price of €9.37, the stock has a 1-day share price return of 2.69% and a 90-day share price return of 12.22%. The 1-year total shareholder...
XTRA:BAYN
XTRA:BAYNPharmaceuticals

Assessing Bayer (XTRA:BAYN) Valuation After Positive Asundexian Stroke Trial Results And Renewed Investor Interest

Bayer (XTRA:BAYN) is back in focus after reporting Phase III OCEANIC-STROKE data for its investigational Factor XIa inhibitor asundexian, showing a 26% reduction in recurrent ischemic strokes without a clear rise in major bleeding. See our latest analysis for Bayer. Those OCEANIC-STROKE results land at a time when Bayer’s share price has already been gathering pace, with a 30 day share price return of 10.36% and a 90 day share price return of 61.89%. Meanwhile, the 1 year total shareholder...